TELO

Announcements

Nothing here yet

Daily updates

• Telomir reported peer-reviewed preclinical data suggesting Telomir-Zn may improve age-related macular degeneration by modulating iron and copper balance, with improved visual outcomes, retinal protection, and reduced mitochondrial oxidative stress in models.Sep 18, 2026

FDA designations

Nothing here yet

News

• Telomir reported a peer-reviewed publication showing Telomir-Zn restored visual function and retinal structure in an AMD modelSep 17, 2026
• Telomir received FDA IND clearance for Telomir-Zn in triple-negative breast cancerApr 30, 2026
• Telomir submitted an IND application to the FDA for Telomir-1 in advanced triple-negative breast cancerMar 31, 2026
• Telomir reports favorable IND-enabling GLP safety results for Telomir-1Dec 18, 2025
• Telomir Pharmaceuticals reports new data showing Telomir-1 significantly reduces PSA levels in human prostate cancer cellsNov 25, 2025